Conference Coverage

VIDEO: Study of hs-cTnT in chest pain intriguing, but flawed


 

AT ACC 14

WASHINGTON – The lack of detectable high-sensitivity cardiac troponin T in patients presenting with chest pain may be a marker of minimal risk of myocardial infarction within 30 days, according to Dr. Nadia Bandstein of the department of medicine at the Karolinska Institute, Solna, Sweden.

She and her colleagues looked at data from all emergency department visits for chest pain during 2010-2012 in Sweden. They found that the negative predictive value of myocardial infarction at 30 days for patients reporting with an hs-cTnT level of less than 5 ng/L, in addition to an ECG showing no blood flow-related damage, was 99.8%. That negative predictive value for death, meaning the patients are not at risk, was 100%.

Discussant Dr. Allan Jaffe of the Mayo Clinic in Rochester, Minn., said in an interview that although these findings are promising, the documentation in this study is not sufficient to use in clinical practice to let patients with these characteristics leave the emergency department.

*Update (3/31/14): This video has been updated.

mzoler@frontlinemedcom.com

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

FDA: Naproxen may pose lower CV risk
MDedge Internal Medicine
Persistent depression doubled coronary heart disease risk
MDedge Internal Medicine
FDA reviewers support approval of platelet inhibitor cangrelor for PCI indication
MDedge Internal Medicine
NSAID makers argue against new warnings on CV risks
MDedge Internal Medicine
No new cardiovascular warnings needed for NSAIDs say FDA advisers
MDedge Internal Medicine
FDA panel votes against cangrelor approval for PCI, bridge indications
MDedge Internal Medicine
No ACS approvals for rivaroxaban, Janssen announces
MDedge Internal Medicine
USPSTF: Insufficient evidence to judge vitamin supplements
MDedge Internal Medicine
RAS blocker prescriptions still lag for ACS patients
MDedge Internal Medicine
'Revolutionary' LDL lowering shown in evolocumab phase III trials
MDedge Internal Medicine